{"entity":{"id":"cytoagents","kind":"company","name":"CytoAgents","aka":["CytoAgents, Inc."],"tldr":"CytoAgents is a Pittsburgh company developing CTO1681, a tablet meant to prevent cytokine release syndrome, a dangerous immune over-reaction that can follow CAR-T cell therapy. It is being tested in an early trial.","summary":"CytoAgents, Inc., based in Pittsburgh, says it was founded in 2018 with a focus on cytokine release syndrome (CRS). Its compound CTO1681 is described by the company as an orally available, steroid-sparing inhibitor of prostaglandin and prostacyclin-mediated inflammation; the website now also lists pulmonary arterial hypertension, asthma, atopic dermatitis and inflammation in the tumour microenvironment as indications. CytoAgents sponsors NCT05905328, a phase 1/2 trial of CTO1681 for the prevention and treatment of CRS in patients receiving CAR T-cell therapy, which ClinicalTrials.gov lists as recruiting. A 2026 National Cancer Institute SBIR award funds work on CTO1681 to prevent and mitigate CRS in people with multiple myeloma receiving CAR T-cell therapy.","asOf":"2026-11-04","links":[{"label":"Official website","url":"https://cytoagents.com/"},{"label":"NIH RePORTER: award 5R44CA295189-02","url":"https://reporter.nih.gov/project-details/11418976"},{"label":"ClinicalTrials.gov: CTO1681 for CRS after CAR T-cell therapy (NCT05905328)","url":"https://clinicaltrials.gov/study/NCT05905328"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":["supportive-care","cell-therapy"],"technologies":[],"targets":[],"drugs":["cto1681"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Company website, the NIH RePORTER record and the ClinicalTrials.gov record for NCT05905328 read on 4 November 2026. NCT05905328 is not yet a trial record in OnCo."],"hq":"Pittsburgh, PA","country":"US","companyType":"biotech","website":"https://cytoagents.com/","founded":2018,"stage":"startup","investors":[],"funding":[{"round":"Grant","year":2026,"amountUsd":936370,"source":"https://reporter.nih.gov/project-details/11418976","note":"NCI SBIR (R44) award 5R44CA295189-02: CTO1681 to prevent and mitigate cytokine release syndrome in multiple myeloma patients receiving CAR T-cell therapy"}]},"route":"/companies/cytoagents/","neighbours":{"cancer":[{"id":"multiple-myeloma","kind":"cancer","name":"Multiple myeloma","route":"/cancers/multiple-myeloma/"}],"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"},{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"drug":[{"id":"cto1681","kind":"drug","name":"CTO1681","route":"/drugs/cto1681/"}]}}